Shin Nippon Biomedical Laboratories, Ltd. (JP:2395)
:2395
Want to see JP:2395 full AI Analyst Report?
Total Valuation
Shin Nippon Biomedical Laboratories, Ltd. has a market cap or net worth of ¥53.29B. The enterprise value is ¥76.01B.
Market Cap¥53.29B
Enterprise Value¥76.01B
Share Statistics
Shin Nippon Biomedical Laboratories, Ltd. has 41,632,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding41,632,400
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Shin Nippon Biomedical Laboratories, Ltd.’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 2.26%.
Return on Equity (ROE)0.11
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)2.26%
Return on Capital Employed (ROCE)0.04
Revenue Per Employee22.32M
Profits Per Employee3.13M
Employee Count1,457
Asset Turnover0.31
Inventory Turnover1.10
Valuation Ratios
The current PE Ratio of Shin Nippon Biomedical Laboratories, Ltd. is 12.9. Shin Nippon Biomedical Laboratories, Ltd.’s PEG ratio is -1.77.
PE Ratio12.9
PS Ratio1.81
PB Ratio1.37
Price to Fair Value1.37
Price to FCF18.67
Price to Operating Cash Flow0.00
PEG Ratio-1.77
Income Statement
In the last 12 months, Shin Nippon Biomedical Laboratories, Ltd. had revenue of 32.52B and earned 4.57B in profits. Earnings per share was 109.69.
Revenue32.52B
Gross Profit15.83B
Operating Income2.65B
Pretax Income6.25B
Net Income4.57B
EBITDA6.09B
Earnings Per Share (EPS)109.69
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Shin Nippon Biomedical Laboratories, Ltd. pays an annual dividend of ¥30, resulting in a dividend yield of 2.79%
Dividend Per Share¥30
Dividend Yield2.79%
Payout Ratio44.72%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.95
52-Week Price Change4.10%
50-Day Moving Average1.43K
200-Day Moving Average1.56K
Relative Strength Index (RSI)40.41
Average Volume (3m)231.41K
Important Dates
Shin Nippon Biomedical Laboratories, Ltd. upcoming earnings date is Aug 5, 2026, TBA (Confirmed).
Last Earnings DateMay 11, 2026
Next Earnings DateAug 5, 2026
Ex-Dividend Date―
Financial Position
Shin Nippon Biomedical Laboratories, Ltd. as a current ratio of 1.09, with Debt / Equity ratio of 95.68%
Current Ratio1.09
Quick Ratio0.71
Debt to Market Cap0.69
Net Debt to EBITDA3.73
Interest Coverage Ratio9.05
Taxes
In the past 12 months, Shin Nippon Biomedical Laboratories, Ltd. has paid 1.71B in taxes.
Income Tax1.71B
Effective Tax Rate0.27
Enterprise Valuation
Shin Nippon Biomedical Laboratories, Ltd. EV to EBITDA ratio is 13.41, with an EV/FCF ratio of 25.88.
EV to Sales2.51
EV to EBITDA13.41
EV to Free Cash Flow25.88
EV to Operating Cash Flow9.80
Balance Sheet
Shin Nippon Biomedical Laboratories, Ltd. has ¥11.57B in cash and marketable securities with ¥36.58B in debt, giving a net cash position of -¥25.01B billion.
Cash & Marketable Securities¥11.57B
Total Debt¥36.58B
Net Cash-¥25.01B
Net Cash Per Share-¥600.78
Tangible Book Value Per Share¥993.63
Margins
Gross margin is 48.66%, with operating margin of 8.16%, and net profit margin of 14.04%.
Gross Margin48.66%
Operating Margin8.16%
Pretax Margin19.21%
Net Profit Margin14.04%
EBITDA Margin18.71%
EBIT Margin8.16%
Analyst Forecast
The average price target for Shin Nippon Biomedical Laboratories, Ltd. is ¥2,090.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target¥2,090.00
Price Target Upside28.85% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast0.34%
EPS Growth Forecast-7.27%